ABCL is trading at $7.33 (4.7% down) in pre-market as the stock extends a two-day pullback following last week’s sharp oncology-driven rally.
- The stock recently surged on optimism surrounding its antibody discovery platform and strategic oncology partnerships.
- Today's pre-market weakness appears to reflect continued profit-taking by investors amid a broadly weaker market backdrop.